IGC Pharma Inc. (NYSE American: IGC) has announced new preclinical findings for its investigational compound IGC-1C, a low-molecular weight drug candidate targeting Alzheimer's disease. The in-vitro data indicate that IGC-1C acts as a modulator of the tau protein's liquid-liquid phase separation (LLPS), a process implicated in the early stages of Alzheimer's and related tauopathies. Experimental results show that IGC-1C inhibits the formation of zinc-mediated tau condensates and promotes their dissolution, suggesting potential to both prevent and reverse initial pathological steps. The compound demonstrated a strong binding affinity to tau (dissociation constant Kd = 3.95 ± 0.32 μM) and was well tolerated in neuroblastoma cell cultures. IGC Pharma plans to conduct further validation studies in animal models as it advances IGC-1C toward clinical trials. The findings have been presented in preclinical studies, with additional results anticipated from forthcoming research.